Ligand binding assays at equilibrium: Validation and interpretation

British Journal of Pharmacology

Volumn 161, Issue 6, 2010, Pages 1219-1237

  Hulme, Edward C ^a   Trevethick, Mike A ^b  

^a NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Allosteric; Antagonist; Buffer; Competitive; Depletion; Enthalpy; Entropy; Equilibrium; GPCR; K d; K dA; Kinetics; Ligand binding assay; Radioligand; Receptor; Temperature

Indexed keywords

ATROPINE; BUFFER; TIOTROPIUM BROMIDE; TRACER; TRITIUM;

ALLOSTERISM; BINDING AFFINITY; BINDING ASSAY; CONCENTRATION RESPONSE; DISSOCIATION CONSTANT; ENTHALPY; ENTROPY; EQUILIBRIUM CONSTANT; HILL REACTION; HUMAN; LIGAND BINDING; PKA; PRIORITY JOURNAL; PROTEIN DEGRADATION; RADIOACTIVITY; RADIOASSAY; RECEPTOR BINDING; REVIEW; STEADY STATE; TEMPERATURE;

ANIMALS; BINDING, COMPETITIVE; BUFFERS; HUMANS; LIGANDS; PROTEIN BINDING; RADIOLIGAND ASSAY; RECEPTORS, DRUG; REPRODUCIBILITY OF RESULTS;

EID: 78049403279     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2009.00604.x     Document Type: Review

References (48)

1. Alexander SPH, Mathie A, Peters JA (2008). Guide to Receptors and Channels (GRAC), 3rd edn (2008 revision). Br J Pharmacol 153 (Suppl. 2): S1-S209.
2. Avlani VA, McLoughlin DJ, Sexton PM, Christopoulos A (2008). The impact of orthosteric radioligand depletion on the quantification of allosteric modulator interactions. J Pharmacol Exp Ther 325: 927-934.
3. Barlow RB, Winter EA (1981). Affinities of the protonated and non-protonated forms of hyoscine and hyoscine n-oxide for muscarinic receptors of the guinea-pig ileum and a comparison of their size in solution with that of atropine. Br J Pharmacol 72: 657-664.
4. Ben Chaim Y, Chanda B, Dascal N, Bezanilla F, Parnas I, Parnas H (2006). Movement of 'gating charge' is coupled to ligand binding in a G-protein-coupled receptor. Nature 444: 106-109.
5. Birdsall NJ, Lazareno S (2005). Allosterism at muscarinic receptors: ligands and mechanisms. Mini Rev Med Chem 5: 523-543.
6. Birdsall NJ, Burgen AS, Hulme EC, Wells JW (1979). The effects of ions on the binding of agonists and antagonists to muscarinic receptors. Br J Pharmacol 67: 371-377.
7. Borea PA, Dalpiaz A, Varani K, Gilli P, Gilli G (2000). Can thermodynamic measurements of receptor binding yield information on drug affinity and efficacy? Biochem Pharmacol 60: 1549-1556.
8. Carter CM, Leighton-Davies JR, Charlton SJ (2007). Miniaturized receptor binding assays: complications arising from ligand depletion. J Biomol Screen 12: 255-266.
9. 50) of an enzymatic reaction. Biochem Pharmacol 22: 3099-3108.
10. Conn PJ, Christopoulos A, Lindsley CW (2009). Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nat Rev Drug Discov 8: 41-54.
11. Copeland RA, Pompliano DL, Meek TD (2006). Drug-target residence time and its implications for lead optimization. Nat Rev Drug Discov 5: 730-739.
12. Davis AM, St Gallay SA, Kleywegt GJ (2008). Limitations and lessons in the use of X-ray structural information in drug design. Drug Discov Today 13: 831-841.
13. 3 receptor. Br J Pharmacol 148: 927-937.
14. Fisher SK (1988). Recognition of muscarinic cholinergic receptors in human SK-N-SH neuroblastoma cells by quaternary and tertiary ligands is dependent upon temperature, cell integrity, and the presence of agonists. Mol Pharmacol 33: 414-422.
15. Freire E (2008). Do enthalpy and entropy distinguish first in class from best in class? Drug Discov Today 13: 869-874.
16. Gessi S, Fogli E, Sacchetto V, Varani K, Merighi S, Leung E et al. (2008). Thermodynamics of A2B adenosine receptor binding discriminates agonistic from antagonistic behaviour. Biochem Pharmacol. 75: 562-569.
17. Glickman JF, Schmid A, Ferrand S (2008). Scintillation proximity assays in high-throughput screening. Assay Drug Dev Technol 6: 433-455.
18. Goldstein A, Barrett RW (1987). Ligand dissociation constants from competition binding assays: errors associated with ligand depletion. Mol Pharmacol 31: 603-609.
19. Heise CE, Sullivan SK, Crowe PD (2007). Scintillation proximity assay as a high-throughput method to identify slowly dissociating nonpeptide ligand binding to the GnRH receptor. J Biomol Screen 12: 235-239.
20. Hulme EC (1999). Analysis of binding data. In: Keen M (ed.). Methods in Molecular Biology: Receptor Binding Techniques. Humana Press Inc: Totowa, NJ, pp. 139-184.
21. Hulme EC, Birdsall NJM (1992). Strategy and tactics in receptor-binding studies. In: Hulme EC (ed.). Receptor-Ligand Interactions - A Practical Approach. IRL Press: Oxford, pp. 63-176.
22. Hulme EC, Soper AK, McLain SE, Finney JL (2006). The hydration of the neurotransmitter acetylcholine in aqueous solution. Biophys J 91: 2371-2380.
23. Lazareno S (1998). Quantification of receptor interactions using binding methods. In: Leff P (ed.). Receptor-based Drug Design. Marcel Dekker Press: New York, NY, pp. 49-78.
24. Lazareno S, Birdsall NJM (1995). Detection, quantitation, and verification of allosteric interactions of agents with labelled and unlabeled ligands at G protein-coupled receptors: interactions of strychnine and acetylcholine at muscarinic receptors. Mol Pharmacol 48: 362-378.
25. Lazareno S, Birdsall NJ (2000). Effects of contamination on radioligand binding parameters. Trends Pharmacol Sci 21: 57-60.
26. 1 muscarinic acetylcholine receptors. Mol Pharmacol 75: 331-341.
27. 2+ release in smooth muscle. Proc Natl Acad Sci USA 106: 11418-11423.
28. May LT, Leach K, Sexton PM, Christopoulos A (2007). Allosteric modulation of G protein-coupled receptors. Annu Rev Pharmacol Toxicol 47: 1-51.
29. Merighi S, Varani K, Gessi S, Klotz KN, Leung E, Baraldi PG et al. (2002). Binding thermodynamics at the human A(3) adenosine receptor. Biochem Pharmacol. 63: 157-161.
30. Motulsky HJ, Mahan LC (1984). The kinetics of competitive radioligand binding predicted by the law of mass action. Mol Pharmacol 25: 1-9.
31. Mou J, Yang J, Shao Z (1994). Tris(hydroxymethyl)aminomethane (C4H11NO3) induced a ripple phase in supported unilamellar phospholipid bilayers. Biochemistry 33: 4439-4443.
32. Pedder EK, Eveleigh P, Poyner D, Hulme EC, Birdsall NJ (1991). Modulation of the structure-binding relationships of antagonists for muscarinic acetylcholine receptor subtypes. Br J Pharmacol 103: 1561-1567.
33. Raffa RB (1999). (Extra)thermodynamics of the drug-receptor interaction. Life Sci 65: 967-980.
34. Rovati GE (1998). Ligand-binding studies: old beliefs and new strategies. Trends Pharmacol Sci 19: 365-369.
35. Ruben AJ, Kiso Y, Freire E (2006). Overcoming roadblocks in lead optimization: a thermodynamic perspective. Chem Biol Drug Des 67: 2-4.
36. Schumacher C, Von TV (1994). Practical instructions for radioactively labelled ligand receptor binding studies. Anal Biochem 222: 262-269.
37. 4 muscarinic receptors: use of NMS/OXO-M ratios to group compounds into potential agonist, partial agonist, and antagonist classes. Neurochem Res 20: 669-674.
38. Stockton JM, Birdsall NJ, Burgen AS, Hulme EC (1983). Modification of the binding properties of muscarinic receptors by gallamine. Mol Pharmacol 23: 551-557.
39. Sullivan SK, Hoare SR, Fleck BA, Zhu YF, Heise CE, Struthers RS et al. (2006). Kinetics of nonpeptide antagonist binding to the human gonadotropin-releasing hormone receptor: implications for structure-activity relationships and insurmountable antagonism. Biochem Pharmacol 72: 838-849.
40. Sum CS, Pyo N, Wells JW (2001). Apparent capacity of cardiac muscarinic receptors for different radiolabeled antagonists. Biochem Pharmacol 62: 829-851.
41. Swillens S (1995). Interpretation of binding curves obtained with high receptor concentrations: practical aid for computer analysis. Mol Pharmacol 47: 1197-1203.
42. Swinney DC (2009). The role of binding kinetics in therapeutically useful drug action. Curr Opin Drug Discov Devel 12: 31-39.
43. Tian WN, Deth RC (1993). Precoupling of Gi/G(o)-linked receptors and its allosteric regulation by monovalent cations. Life Sci 52: 1899-1907.
44. Wang ZX, Jiang RF (1996). A novel two-site binding equation presented in terms of the total ligand concentration. FEBS Lett 392: 245-249.
45. Warne T, Serrano-Vega MJ, Baker JG, Moukhametzianov R, Edwards PC, Henderson R et al. (2008). Structure of a beta1-adrenergic G-protein-coupled receptor. Nature 454: 486-491.
46. Weiland GA, Minneman KP, Molinoff PB (1979). Fundamental difference between the molecular interactions of agonists and antagonists with the beta-adrenergic receptor. Nature 281: 114-117.
47. Wells JW, Birdsall NJ, Burgen AS, Hulme EC (1980). Competitive binding studies with multiple sites. Effects arising from depletion of the free radioligand. Biochim Biophys Acta 632: 464-469.
48. 2-Galpha I1 fusion protein. J Biochem 135: 589-596.